Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stepwise dose escalation of febuxostat to prevent gout flares
ChiCTR1900028169Phase 4Recruiting
- Sponsor
- Anqing City Hospital
- Start
- Jan 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of febuxostat and colchicine in gout (3 arms), sponsored by Anqing City Hospital. Primary endpoint: Blood uric acid. Started Jan 2020; status: recruiting.
02
Drugs
febuxostatcolchicine
03
Conditions
gout
Beyond the preview
Go deeper on ChiCTR1900028169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028169.